The opioid market is dominated by non-tamper resistant formulations (TRFs), but the Food and Drug Administration’s (FDA’s) promotion of TRF therapies could well result in the departure of non-TRF therapies from the market and shake up its structure. Purdue Pharma’s Oxycontin is the only opioid pain more
To use all functions of this page, please activate cookies in your browser.